Bivalirudin vs Heparin in ECMO Patients

• Status: Withdrawn
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label, randomized study comparing the clinical outcomes of unfractionated Heparin and Bivalirudin for anticoagulation in adult subjects requiring ECMO support.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Bivalirudin; Calcium heparin; Heparin; Hirudins

Criteria

Inclusion Criteria:

• Adult patients on veno-arterial (VA) or veno-venous (VV)ECMO

Exclusion Criteria:

• Patient or surrogate decision makers cannot provide informed consent.

• Patients who have intolerance to either heparin or bivalirudin

• Patients who received any form of thrombolytic therapy within the past 30 days.